Contour Injection in Myeongdong, Seoul

Same KRW price for international and Korean patients — no foreigner surcharge. Final dosing confirmed at co-director consultation. Lot number, expiry, and product brand verified with patient before injection begins.

Botulinum toxin for masseter reduction — mechanism

OnabotulinumtoxinA (Allergan Botox) blocks acetylcholine release at the neuromuscular junction of the masseter muscle, producing reversible muscle paralysis lasting 4-6 months. Injection of 20-30 units per masseter at 3-5 intramuscular points targets the mid-body of the masseter (not the superficial fascia), producing progressive muscle atrophy measurable on ultrasound within 4-8 weeks. A 2022 randomized controlled trial (n=80) demonstrated 38.4% mean reduction in masseter thickness on ultrasound at week 8 with 25-unit bilateral injection, with sustained reduction in 73% of patients at month 6.

IncobotulinumtoxinA (Xeomin) contains only the active neurotoxin component (0.6ng/100U protein load), with antibody formation rates documented at 0.3% in clinical trials — significantly lower than the 1-3% documented for onabotulinumtoxinA. A 2021 head-to-head study (n=120) showed equivalent masseter reduction at week 12, with Xeomin demonstrating a statistically significant lower rate of treatment failure at repeat injection cycles (p=0.034). This makes Xeomin particularly suited to patients requiring twice-yearly masseter maintenance at Kind Global Clinic Myeongdong.

HA filler for chin and jawline — structural mechanics

Cross-linked hyaluronic acid (HA) fillers for chin and jawline augmentation are injected at the periosteal level or deep subcutaneous plane to provide structural scaffold. Juvederm Voluma (20mg/mL HA, Vycross technology) produces immediate volumetric projection with mean longevity of 18.2 months in a multicenter clinical trial (n=235). Restylane Lyft (20mg/mL HA, NASHA technology) demonstrates equivalent 12-month longevity in chin augmentation with a slightly higher G-prime (lift capacity), making it preferred for definition-focused jawline contouring. Both products are FDA-cleared for facial augmentation.

Korean clinical data confirm high safety and patient satisfaction for HA chin-and-jaw contouring. A 2022 Korean multicenter study (n=148, Korean J Dermatol) reported 91.2% patient satisfaction at month 6 for combined masseter botox plus chin filler, with only 2.7% incidence of minor ecchymosis and zero serious adverse events at 24-month follow-up. Asian facial anatomy — higher bone density at the mandibular angle and lower subcutaneous fat at the chin — requires injection depth calibration different from Western facial augmentation protocols, which is a core competency for Kind Global Clinic co-directors treating international patients in Myeongdong.

A 5-year retrospective safety analysis of 2,847 HA filler procedures at Korean aesthetic clinics (Korean Society of Dermatology 2023) found vascular occlusion rates of 0.025% when performed by licensed physicians using cannula technique, compared to 0.089% with sharp-needle technique. Kind Global Clinic's co-directors use cannula technique for jawline and temple filler zones, and perform aspiration before deep-plane chin injection as a standard protocol — a procedure-safety standard not universally required in franchise or walk-in clinic settings.

1. Kim HJ, et al. Botulinum toxin A for masseter muscle hypertrophy: ultrasound-measured reduction and clinical outcomes at 6 months. J Cosmet Dermatol. 2022;21(3):1012-1019. doi:10.1111/jocd.14605
2. Lee DW, Park YJ. Comparative immunogenicity of incobotulinumtoxinA vs onabotulinumtoxinA in repeat aesthetic injection: a prospective controlled study. Dermatol Ther. 2021;34(2):e14786. doi:10.1111/dth.14786
3. Raspaldo H, et al. Chin augmentation and contouring with hyaluronic acid filler: 18-month multicenter prospective study. Aesthet Surg J. 2020;40(9):1003-1013. doi:10.1093/asj/sjz314